TRCT
KLRS

Tower Research Capital (TRC)’s Kalaris Therapeutics KLRS Stock Holding History

Tower Research Capital (TRC)’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4K Buy
2,560
+2,421
+1,742% +$12.6K ﹤0.01% 3981
2026
Q1 		$802 Buy
+139
New +$1.23K ﹤0.01% 4775
2025
Q3 		– Sell
-2,153
Closed -$5.75K – 5756
2025
Q2 		$5.75K Buy
2,153
+719
+50% +$3.25K ﹤0.01% 4154
2025
Q1 		$11.5K Buy
1,434
+675
+89% +$6.61K ﹤0.01% 3532
2024
Q4 		$7.33K Buy
759
+658
+651% +$9.95K ﹤0.01% 4084
2024
Q3 		$1.88K Sell
101
-793
-89% -$13.9K ﹤0.01% 5087
2024
Q2 		$14.9K Buy
894
+452
+102% +$7.98K ﹤0.01% 3929
2024
Q1 		$7.68K Sell
442
-187
-30% -$3.05K ﹤0.01% 4167
2023
Q4 		$9.84K Buy
629
+351
+126% +$13.8K ﹤0.01% 4340
2023
Q3 		$13.7K Sell
278
-101
-27% -$6.88K ﹤0.01% 3755
2023
Q2 		$29.7K Buy
379
+288
+316% +$27.4K ﹤0.01% 3032
2023
Q1 		$8K Sell
91
-243
-73% -$31K ﹤0.01% 4682
2022
Q4 		$39K Buy
334
+205
+159% +$34.8K ﹤0.01% 2536
2022
Q3 		$23K Sell
129
-157
-55% -$24.5K ﹤0.01% 3832
2022
Q2 		$26K Buy
286
+49
+21% +$5.14K ﹤0.01% 3527
2022
Q1 		$37K Buy
237
+104
+78% +$20.7K ﹤0.01% 2972
2021
Q4 		$40K Buy
133
+24
+22% +$11.1K ﹤0.01% 2955
2021
Q3 		$63K Buy
109
+14
+15% +$6.48K ﹤0.01% 2774
2021
Q2 		$43K Buy
95
+23
+32% +$11.9K ﹤0.01% 3154
2021
Q1 		$38K Sell
72
-180
-71% -$151K ﹤0.01% 3362
2020
Q4 		$223K Buy
252
+93
+58% +$71.5K 0.01% 1622
2020
Q3 		$101K Buy
+159
New +$109K ﹤0.01% 3140

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tower Research Capital (TRC)'s KLRS Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Kalaris Therapeutics (KLRS) stake by 1,742% in Q2 2026, buying an estimated $12.6K and bringing the position to 2,560 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3981.

Tower Research Capital (TRC) first reported a position in KLRS in Q3 2020 and has held it in 22 quarters since. The position peaked at $223K in Q4 2020. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Tower Research Capital (TRC) held 2,560 shares of Kalaris Therapeutics worth $10.4K as of Q2 2026.
  • Tower Research Capital (TRC) bought 2,421 Kalaris Therapeutics shares in Q2 2026, an estimated $12.6K.
  • Kalaris Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3981 holding.
  • Tower Research Capital (TRC) first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s Kalaris Therapeutics position peaked at $223K in Q4 2020.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.